Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma: a Multicenter, Non-interventional, Retrospective Survey
Because State Food and Drug Administration (SFDA) exempted manufacturers from conducting
clinical trials of Sunitinib in China, overall efficacy and safety data of Sunitinib in
Chinese patients with renal cell carcinoma were deficiency. The investigators carried out
this research project will be sufficient evidence, and help clinicians in China to make
decision in real daily practice.
Observational Model: Cohort, Time Perspective: Retrospective
Disease control rate (DCR)
To determine the Disease control rate (DCR) defined as the percentage of patients who have a partial response (CR) or complete response (PR) to Sunitinib plus those whose disease is stable (DS). To determine the Objective Responsive Rate (ORR) defined as the percentage of patients who have a partial response (PR) or complete response (CR) to Sunitinib.
2008-2011 (up to 3 years)
Zhangqun Ye, MD
China: Food and Drug Administration